E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017770 |
E.1.2 | Term | Gastric carcinoma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Compare overall 5-year survival rates in patients surgically treated for advanced gastric adenocarcinoma (T3, T4 and/or N+ and/or with positive cytology), treated either with curative gastrectomy and adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (Arm A), or with curative gastrectomy alone (Arm B). |
|
E.2.2 | Secondary objectives of the trial |
- Compare 3-year and 5-year recurrence-free survival; - Study the incidence of locoregional recurrence and compare locoregional recurrence-free 5-year survival; - Assess and compare treatment-related toxicity (Common Terminology Criteria for Adverse Events v4.0); - Compare sites of recurrence; - Identify prognostic factors of overall 5-year survival and recurrence-free 5-year survival; - Compare patients’ quality of life at preoperative time, M3, M6 and M12 and changes of quality of life.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
No specific title, date and version : sub-study included in GASTRICHIP protocol.
Objective : Compare the incidence of positive peritoneal cytology pre- and post-gastrectomy in two arms of the study (Am A and Arm B), and assess its impact on 5-year survival. |
|
E.3 | Principal inclusion criteria |
-18 < age ≤ 75 years old - White blood cells > 3,500/mm3, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3 - Good renal functions, serum creatinine values being < 1.5 mg/dl - Performance Status ≤1, Karnofsky Index ≥ 70% - Serum bilirubin ≤ 2 mg/dl - Having given written informed consent prior to any procedure related to the study. - Covered by a Health System where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research - Not under any administrative or legal supervision Specific to the study - Histologically evidenced resectable T3 or T4 gastric adenocarcinoma for which a curative gastrectomy is scheduled, with invasion into the serosa AND/OR lymph node metastasis (determined from data obtained by endoscopic ultrasound and chest, abdomen and pelvis CT scan) AND/OR positive peritoneal cytology (sampled during the preoperative laparoscopy). AND/OR - Perforated gastric adenocarcinoma AND/OR - Siewert III adenocarcinoma of the cardia for which a gastrectomy by exclusive abdominal laparotomy is scheduled
|
|
E.4 | Principal exclusion criteria |
- Prior malignant tumors with detectable signs of recurrence - Gastric stump adenocarcinoma - Presence of comorbidities, notably serious chronic diseases or organ failure - Any subject in exclusion period of a previous study according to applicable regulations - Pregnancy or breastfeeding - Females of childbearing age potential not using medically accepted contraceptive measures, as judged by the investigator Interfering substance - Contraindication to any drug contained in the chemotherapy regimen - Life threatening toxicity before surgery - Distant metastases (liver, lung. ovaries, etc) - Tumoral infiltration of the head or body of the pancreas - Patients presenting an adenocarcinoma of the cardia Siewert I or II - Existence of macroscopic peritoneal implants - Patients with clinically significant ascites (> 500 cc) even if cytology is negative for cancer cells, in the absence of other non-malignant causes of ascites
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
5 years (end of follow-up) |
|
E.5.2 | Secondary end point(s) |
1) Recurrence-free survivals (peritoneal recurrence, locoregional recurrence, metastatic recurrence, site of recurrence ) 2) Treatment-related toxicity 3) Treatment-related mortality 4) Treatment related morbidity 5) Quality of life |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) 3 years and 5 years 2) During the 60th postoperative days 3) During the 60th postoperative days 4) During the 60th postoperative days 5) At preoperative time, M3, M6 and M12 postoperative |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Curative gastrectomy with D1-D2 lymph node dissection alone (without HIPEC with oxaliplatin) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 8 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |